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Key Points
 The goal was to determine the importance of the sodium–glucose cotransporter SGLT1 and
the glucose uniporter GLUT2 in intestinal glucose absorption during oral glucose tolerance
tests (OGTTs) in mice.
 Glucose absorption was determined in mice using positron emission tomography and three
non-metabolizable glucose probes: one specific for SGLTs, one specific for GLUTs, and one a
substrate for both SGLTs and GLUTs.
 Absorption was determined in wild-type, Sglt1−/− and Glut2−/− mice.
 Gastric emptying was a rate-limiting step in absorption.
 SGLT1, but not GLUT2, was important in fast glucose absorption.
 In the absence of SGLT1 or GLUT2, the oral glucose load delivered to the small intestine was
slowly absorbed.
 Oral phlorizin only inhibited the fast component of glucose absorption, but it contributed to
decreasing blood glucose levels by inhibiting renal reabsorption.
Abstract The current model of intestinal absorption is that SGLT1 is responsible for trans-
port of glucose from the lumen into enterocytes across the brush border membrane, and
GLUT2 for the downhill transport from the epithelium into blood across the basolateral
membrane. Nevertheless, questions remain about the importance of these transporters in
vivo. To address these questions, we have developed a non-invasive imaging method, positron
emission tomography (PET), to monitor intestinal absorption of three non-metabolized glucose
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tracers during standard oral glucose tolerance tests (OGTTs) in mice. One tracer is specific
for SGLTs (α-methyl-4-[18F]fluoro-4-deoxy-D-glucopyranoside; Me-4FDG), one is specific for
GLUTs (2-deoxy-2-[18F]fluoro-D-glucose; 2-FDG), and one is a substrate for both SGLTs and
GLUTs (4-deoxy-4-[18F]fluoro-D-glucose; 4-FDG). OGTTs were conducted on adult wild-type,
Sglt1−/− and Glut2−/− mice. In conscious mice, OGTTs resulted in the predictable increase in
blood glucose that was blocked by phlorizin in both wild-type and Glut2−/− animals. The blood
activity of both Me-4FDG and 4-FDG, but not 2-FDG, accompanied the changes in glucose
concentration. PET imaging during OGTTs further shows that: (i) intestinal absorption of the
glucose load depends on gastric emptying; (ii) SGLT1 is important for the fast absorption;
(iii) GLUT2 is not important in absorption; and (iv) oral phlorizin reduces absorption by SGLT1,
but is absorbed and blocks glucose reabsorption in the kidney. We conclude that in standard
OGTTs in mice, SGLT1 is essential in fast absorption, GLUT2 does not play a significant role, and
in the absence of SGLT1 the total load of glucose is slowly absorbed.
(Resubmitted 28 March 2018; accepted after revision 17 April 2018; first published online 15 May 2018)
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Introduction
Glucose, in the formof complex carbohydrates, constitutes
a major source of calories in the human diet, about 250 g
per day in a 70 kg adult. All of the ingested glucose is
normally absorbed in the intestine, and the molecular
mechanisms are thought to be well understood. Active
absorption occurs across themature enterocytes lining the
small intestine, first, by the sodium glucose cotransporter
(SGLT1) in the brush border membrane, and second,
by a glucose uniporter in the basolateral membrane
(GLUT2) (Wright et al. 2011). Nevertheless, questions
still remain about the relative importance of these trans-
port proteins in glucose absorption in vivo after a meal
in both humans and rodents, especially at high glucose
loads.
The oral glucose tolerance test (OGTT) is an important
tool in evaluating glucose absorption, although it is
primarily used to assess insulin regulation of blood
glucose. In such tests, a standard ‘meal’, i.e. 1–2 g of glucose
per kg body weight, is administered as a bolus of 1–2 M
glucose and the changes in plasma glucose are monitored
as a function of time. However, it is a non-trivial task to
interpret the data with respect to intestinal absorption
owing to the complex and often interacting processes
controlling plasma glucose levels. These include gastric
emptying, glucose absorption, uptake, metabolism and
release in multiple organs, as well as regulation of these
processesbyneural andendocrine inputs. In animals, it has
been popular to usemore invasive in vivo techniques, such
as perfusion of isolated intestinal loops (Debnam& Levin,
1975), where absorption, measured by glucose, galactose
or α-methyl-D-glucopyranoside (αMDG) disappearance
from the perfusate, occurred via two components,
namely a saturable process at low concentrations and
a non-saturable process at high concentrations. Studies
by Kellett (Kellett, 2001; Kellett & Brot-Laroche, 2005)
led to the controversial hypothesis that the ‘diffusion
component’ in mice is carried out by GLUT2 recruited
into the brush border membrane from the cytoplasm.
It is noteworthy that αMDG is not a substrate for
GLUT2.
In this work, we have turned to a novel method,
positron-emission tomography (PET), to follow the
dynamics of glucose absorption during OGTTs in
mice using non-metabolizable SGLT- and GLUT-specific
probes (Sala-Rabanal et al. 2016). A major advantage of
PET is that it is a non-invasive technique to record the
distribution of the glucose tracers throughout the whole
mouse with high spatial (2 mm) and temporal resolution.
In addition to wild-type mice, we have also used Sglt1−/−
and Glut2−/− mice (Sala-Rabanal et al. 2016).
Our results show that the rate of gastric emptying limits
glucose intestinal absorption, SGLT1 has a key role in the
fast absorption of glucose from the duodenum, but neither
SGLT1 nor GLUT2 is essential for the total absorption of
glucose over the duration of OGTTs.
Methods
Animals
All animal procedures followed guidelines approved by
the University of California Chancellor’s Committee
on Animal Research and the National Institutes of
Health. We understand the ethical principles under
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 596.13 Glucose absorption in vivo 2475
which The Journal of Physiology operates and our
work complies with the animal ethics policy and
checklist as outlined recently (Grundy, 2015). Generally,
experiments were carried out on mice used in our
prior study to determine the I.V. biodistribution of
α-methyl-4-[18F]fluoro-4-deoxy-D-glucopyranoside
(Me-4FDG), 2-deoxy-2-[18F]fluoro-D-glucose (2-FDG)
and 4-deoxy-4-[18F]fluoro-D-glucose (4-FDG)
(Sala-Rabanal et al. 2016). The animals include
male and female wild-type C57Bl/6 mice from The
Jackson Laboratory (Bar Harbor, ME, USA); and female
Glut2–/– mice and male Sglt1–/– mice on a C57Bl/6
background (Thorens et al. 2000; Gorboulev et al. 2012).
The control experiments for the Sglt1–/– and Glut2−/−
mice were conducted on the same-sex wild-type mice.
Preliminary studies did not reveal differences between
sexes, or between mouse strains. For some experiments,
we usedwild-typeC57Bl/6micewith indwelling duodenal
catheters (Taconic Biosciences, Hudson, NY, USA). All
animals were housed at the UCLA Division of Laboratory
Animal Medicine facilities, and maintained on a 12 h
light–dark cycle, with food and water available ad libitum.
Sglt1–/– mice were kept on a low carbohydrate diet (Teklad
TD08212; Harlan, Indianapolis, IN, USA) to avoid
diarrhoea caused by glucose–galactose malabsorption
(Wright et al. 2001; Gorboulev et al. 2012). Prior to each
study, mice were fasted overnight in cages with free access
to water. Experiments were conducted between 10.00 and
14.00 h. At the termination of the studies, animals were
killed by terminal exsanguination under deep isoflurane
anaesthesia (Abbott Laboratories, Chicago, IL, USA),
followed by thoracotomy.
Radiochemistry, probe metabolism and selectivity
2-FDG was obtained from the UCLA Biomedical
Cyclotron, and Me-4FDG and 4-FDG were synthesized
as described (Yu et al. 2010, 2013; Wright et al. 2014;
Sala-Rabanal et al. 2016) from the corresponding
acetylated galactose triflate by radiofluorination
with cyclotron-produced [18F]fluoride, followed by
deacetylation. Probes had high chemical and radio-
chemical purities (> 97%) and specific radioactivity
(> 2000 Ci mmol−1) (Wright et al. 2014). As previously
demonstrated, 2-FDG is a preferred substrate for GLUTs
(K0.5 7 mM for hGLUT2 and > 300 mM for hSGLT1),
Me-4FDG is a preferred substrate for SGLTs (K0.5 0.06mM
for hSGLT1 and 14 mM for hGLUT2), and 4-FDG is a
substrate for both GLUTs and SGLTs (K0.5 14 mM for
hGLUT2 and 0.1 mM for hSGLT1). Neither Me-4FDG
nor 4-FDG is phosphorylated by hexokinase in vitro or
metabolized in vivo, whereas 2-FDG is phosphorylated
intracellularly by hexokinase to 2-FDG-6-phosphate (Yu
et al. 2010; Sala-Rabanal et al. 2016).
Simultaneous OGTT and blood tracer determination
Mice (20-40 g) were given 1mg g−1 phlorizin (100–200μl
of a 20% solution in propylene glycol) or the appropriate
volume of excipient as a control, directly into the stomach,
using a bulb-tipped gastric gavage needle. Twentyminutes
later, this was followed by gavage of 2 mg g−1 glucose
(100–200μl of a 1.3M glucose solution inwater containing
300–500μCiMe-4FDG, 2-FDGor 4-FDG). Blood glucose
levels were determined immediately before phlorizin
(or vehicle) pre-treatment (i.e. fasting baseline), and at
selected times after delivery of the glucose/tracer bolus in
conscious mice (i.e. at 15, 30, 45, 60 and 120 min). Blood
(1 μl) was obtained from a small tail vein puncture and
assayedwith a commercial glucosemeter (Contour; Bayer,
Leverkusen, Germany). Subsequently, the glucose meter
strips were counted for fluorine-18 activity in a gamma
counter (1480Wizard; PerkinElmer,Waltham,MA,USA).
Animals were lightly anaesthetized with 1% isoflurane
prior to the gavage interventions, but otherwise allowed
to roam freely in their holding cage for the duration of the
experiment, and handled for less than 1min at each blood
collection.
In vivo microPET scanning and data analysis
Experiments were performed at the Preclinical Imaging
Technology Centre of the UCLA Crump Institute for
Molecular Imaging. A MicroPET Focus 220 scanner (CTI
Concorde Microsystems, Knoxville, TN, USA) was used
for PET data acquisition where all data were corrected
automatically for 18F decay. To determine the absorption
and tissue distribution of orally delivered glucose radio-
tracers inmice, animalswere lightly anaesthetizedwith 1%
isoflurane and administered300μCi 2-FDG,Me-4FDG
or 4-FDG by orogastric gavage. Where indicated, the
tracers were delivered in a solution containing 2 mg g−1
glucose, following pre-treatment with 1 mg g−1 phlorizin
in propylene glycol or vehicle as described above. For
conscious studies (Figs 4 and 6, and Table 1), mice were
returned to their holding cage after gavage and allowed to
roam freely. Ten minutes before the scan was scheduled to
start, mice were anaesthetized in a heated induction box
by inhalation of 2% isoflurane in 100%oxygen, positioned
on a heated custom PET-CT small animal holder, which
allows for continuous anaesthesia (Suckow et al. 2009),
and PET-scanned for 10 min. For dynamic microPET
studies (Figs 5, 7 and 8), anaesthetized animalswere placed
on the PET-CT holder immediately after oral gavage and
a 1 h PET scan promptly started; a delay of approximately
2 min between tracer delivery and scan initiation has
been taken into account when representing the data. To
assess absorption and distribution of the tracers when
delivered directly to the intestine (Fig. 9), mice with a
duodenal catheter were anaesthetized, and positioned on
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 1. Bio-distribution of orally delivered glucose PET tracers Me-4FDG, 2-FDG and 4-FDG in mice
Percentage of absorbed tracer in target organ
Me-4FDG 2-FDG 4-FDG
Organ Wild-type Glut2−/− Wild-type Glut2−/− Wild-type Glut2−/−
Brain 0.29 ± 0.04b 0.1, 0.3b 3.7 ± 0.7ab 4.9 ± 1.2a 4.0 ± 1.5a,b 2.5 ± 0.5a,b
Heart 1.4 ± 0.2 1.1, 1.3 3.1 ± 0.7 2.1 ± 0.5 2.0 ± 0.6 1.7 ± 0.3
Muscle 0.30 ± 0.03a 0.3, 0.2a,b 0.11 ± 0.03b 0.13 ± 0.02b 0.13 ± 0.03b 0.15 ± 0.03a,b
Kidney 0.9 ± 0.1b 6, 5a 1.1 ± 0.2b 3.8 ± 0.9a 1.4 ± 0.3b 5.7 ± 0.9a
Bladder 1.4 ± 0.4b 19, 17a,b 19 ± 3a 14 ± 3a,b 7 ± 2a,b 13 ± 3a,b
Data are from the same experiments as in Fig. 4. Results are mean ± SEM of 6–14 experiments except for Me-4FDG in Glut2−/− mice,
where the individual values are shown instead. For each target organ (brain, heart, muscle, kidney, or urinary bladder), significant
differences in tracer uptake between wild-type and Glut2-null animals are indicated by different lowercase letters (P < 0.05, two way
ANOVA and Tukey’s test). Kidney refers to the right kidney, and Muscle refers to a 64 mm3 spherical VOI from the inner right thigh
(the same in all mice).
the scanning bed. A 1 h PET scan was initiated after
infusion into the duodenum of 200 μl of a 0.9% NaCl
solution containing 200μCiMe-4FDGand5mMα-MDG;
or 200 μCi 2-FDG and 5 mM 2-deoxy-D-glucose (2-DG);
or 200 μCi 4-FDG and 5 mM glucose.
For dynamic scans of the anaesthetized whole mouse,
the acquired data were binned into 25 image frames (3 ×
20, 4 × 30, 5 × 60, 5 × 120, 3 × 180, 3 × 300, and 2 ×
600 s for Figs 5, 8 and 9; or 1 × 1.75, 11 × 0.5, 1 × 1,
1 × 8.75, 1 × 24, 1 × 106, 1 × 240, 1 × 380, 1 × 240,
1 × 380, 1 × 500, 1 × 570, 1 × 675, 1 × 725 and 1 × 355
s for Fig. 7).
After completion of the PET data acquisition, 10 min
computed tomography (CT) scans were performed to
provide anatomical information, using a MicroCAT II
X-ray Tomograph (ImTek Inc., Knoxville, TN, USA). PET
images were reconstructed using Fourier rebinning and
a filtered back-projection algorithm (Kreissl et al. 2011;
Wong et al. 2013), andmicroCT images were co-registered
with microPET data for attenuation correction (Chow
et al. 2005). AMIDE software (Loening & Gambhir, 2003)
was used for image display and volume-of-interest (VOI)
analysis.
Gastric emptying and intestinal absorption were
estimated by determining tracer concentration in stomach
and small intestine as a function of time. The approach
is explained in Fig. 1 where the distribution of 2-FDG
in wild-type and Glut2−/− mice 60 min after gavage is
shown. In each experiment, volumes of interest (VOI) for
the whole mouse, stomach (st), intestine (in), brain (br)
and bladder (bl) were drawn, and the activity of tracer
(μCi) in each VOI at 60 min was estimated using Amide
software (Loening & Gambhir, 2003). Gastric emptying
was obtained from the difference between the initial and
final activities in the stomach VOI; the initial amount
gavaged was estimated from the activity detected in the
whole-mouse VOI, which was within a small percentage
of that measured in the administered gavage solution
(100–500 μCi). Intestinal absorption of the tracer that
was emptied into the stomachwas estimated from the total
activity in thewhole bodyminus the sumof that remaining
in the stomach and in the intestine. The approach is
validated by the accumulation of absorbed tracer in the
min
max
Glut2-/-
2-FDG
Wild-type
2-FDG
ss cc
bl
bl
bl
bl
in
in
inin
h
br br
h h
h
st
Figure 1. Distribution of 2-FDG in representative wild-type
and Glut2–/– mice 60 min after gavage to illustrate the
determination of gastric emptying and intestinal absorption
For each mouse, coronal (c) and sagittal (s) sections (0.2 mm thick)
are shown, and the areas corresponding to the three-dimensional
volumes of interest (VOIs) for intestine (in), stomach (st), brain (br),
heart (h) and urinary bladder (bl) are delineated. Images are
displayed according to the NIH intensity scale for tracer activity, from
red (highest), through green (intermediate) to purple (lowest). VOI
analysis was performed using Amide software. Gastric emptying was
estimated from the difference between the 2-FDG measured in the
whole-body VOI and the amount remaining in the stomach, and
intestinal absorption was estimated from the amount of 2-FDG in
the whole body minus the sum of the amounts detected in the
stomach and the small intestine.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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brain, bladder and heart following oral delivery of 2-FDG
(Fig. 1). In these examples, 125 μCi of 2-FDG in 200 μl
of 1.3 M glucose (260 μmol of glucose) was injected into
the stomach at the start of the OGTT. After 60 min, 24
(wild-type; Fig. 1, left) and 46μCi (Glut2−/−; Fig. 1, right)
remained in the stomach, 20 and 15 μCi in the intestine;
10 and 8 μCi accumulated in brain and 30 and 27 μCi in
the urinary bladder. Therefore in 60min, 81% and 63% of
the initial amount in the stomach (211 and 164 μmol of
glucose) was emptied into the intestine, 80% and 92% of
the amount entering the intestine was absorbed (169 and
151μmol), 13%of the amount absorbedwas takenup into
the brain, and 30% and 27% (51 and 41 μmol of glucose)
was excreted into the urinary bladder. Given the specific
activity of the gavage solution, i.e. 260μmol and 125μCi,
gastric emptying, intestinal absorption, renal excretion
and uptake into each organ may also be expressed in
moles h−1.
Statistical analysis
SigmaPlot 10.0 (Systat Software, San Jose, CA, USA) and
CorelDRAW X8 18.1 (Corel Corp., Mountain View, CA,
USA) were used for figure preparation. Unless otherwise
noted, data are shown as mean ± SEM of at least three
experiments. Statistical analyses were performed with
Origin (OriginLab Corp., Northampton, MA, USA). The
differences in blood glucose levels between wild-type and
Glut2−/− in OGTTs (Fig. 2) were tested by means of
one-way ANOVA followed by post hoc all-pairwise Tukey’s
test. The differences in 60min conscious gastric emptying,
ababab
ab
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9
6
3
0
0 20 40 60 80 100 120
min after bolus
Wild-type
Glut2-/-
b
bG
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co
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ab
ab
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Figure 2. Standard OGTTs in wild-type and in Glut2–/– mice
Time course of blood glucose levels after orogastric gavage of
2 mg g−1 of glucose. Data are means ± SEM from 10 (wild-type) or
4 (Glut2–/–) mice. Groups that share letters are statistically similar (‘a’
and ‘ab’, or ‘b’ and ‘ab’), whereas those not sharing any letters (‘a’
and ‘b’) are significantly different (P < 0.05, one-way ANOVA and
Tukey’s test).
absorption and accumulation into target organs, i.e. brain,
heart, muscle, kidney and urinary bladder (Fig. 4 and
Table 1) were evaluated by means of two-way ANOVA
followed by the Tukey’s test, using tracer (Me-4FDG,
2-FDG or 4-FDG) and genotype (wild-type or Glut2−/−)
as independent variables. Where appropriate, the results
of the statistical analysis are indicated by a lowercase letter
system, whereby groups that share letters are statistically
similar (for example, ‘a’ and ‘ab’, or ‘b’ and ‘ab’),
whereas those not sharing any letters are significantly
different (P < 0.05; for example, ‘a’ and ‘b’). Additionally,
where indicated, Student’s t test was applied to examine
differences between treatments.
Results
OGTT
Following an overnight fast and just prior to OGTT
experiments, blood glucose was consistently between 4
and 6 mM (see Figs 2 and 3), that is, within the normal
range. After gavage with 200 μl of 2 mg g−1 of glucose
(1.3 M), the blood glucose level rose to peak at 12–14 mM
within 60 min, and then declined slowly towards base-
line (Figs 2 and 3). When mice were pre-treated with
1 mg g−1 phlorizin, the blood glucose concentration
remained relatively flat at the fasting level, but it did
increase slowly by up to 3 mM (Fig. 3). As phlorizin is
a high affinity, specific competitive inhibitor of SGLTs,
at least at low concentrations (< 100 μM), this has been
taken as evidence for the importance of SGLT1 in glucose
absorption.OGTTswere also conducted onGlut2−/− mice
with similar results (Fig. 2) and there were no statistically
significant differences between blood glucose levels at each
time point, except for a small difference in the fasting
levels.When the data were normalized to the fasting blood
glucose levels, the data points for the two studies over-
lapped (not shown).
Simultaneous evaluation of Me-4FDG, 2-FDG and
4-FDG levels in blood during the OGTTs show
that Me-4FDG and 4-FDG activity in control and
phlorizin-treated mice closely followed the blood glucose
levels (Fig. 3A and C). This was not the case for 2-FDG
(Fig. 3B), where the activity in blood increased slowly
in both the presence and absence of phlorizin, at rates
comparable to those for Me-4FDG and 4-FDG in the pre-
sence of phlorizin. Our interpretation is that Me-4FDG
and 4-FDG are tracers for glucose absorption in vivo, but
2-FDG is not. Furthermore, given that Me-4FDG is not a
preferred substrate for GLUT2, and 2-FDG is not a pre-
ferred substrate for SGLT1 (Sala-Rabanal et al. 2016), these
results point to an important role of SGLT1, and a minor
role of GLUTs in glucose absorption during OGTTs in
mice.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Gastric emptying, intestinal absorption and tissue
distribution of orally delivered glucose PET tracers in
conscious mice
Preliminary studies indicated that gastric emptying was
similar in conscious and isoflurane-anaesthetizedmice. In
conscious mice, the biodistribution of Me-4FDG, 2-FDG
and 4-FDG 60 min after oral gavage was determined from
10 min microPET scans in both wild-type and Glut2−/−
mice (Fig. 4 and Table 1). The percentage of each tracer
remaining in the stomach and the percentage of tracer
absorbed from the intestine into the body are summarized
in Fig. 4B and 4C. On average, gastric emptying by 1 h was
60% for all tracers, but this was highly variable from
one mouse to another, i.e. 15–100% (Fig. 4B). In both
control and Glut2−/− mice, absorption of the Me-4FDG
and 4-FDG that were delivered into the small intestine
was virtually complete (90%) 60 min after oral delivery,
whereas absorptionof 2-FDGwas slightly lower, i.e.80%
on average, and more variable in both sets of mice. In
the small intestine, 2-FDG activity was apparent in both
wild-type and Glut2−/− mice while Me-4FDG and 4-FDG
were visible only in the Glut2−/− mice (Fig. 4A).
As summarized in Table 1, the biodistribution of
absorbedMe-4FDG, 2-FDGand4-FDG in themice shown
in Fig. 4 was similar to that reported after I.V. injection
of the tracers into the body (Sala-Rabanal et al. 2016).
Thus, 2-FDG and 4-FDG were taken up into the brain,
heart, skeletal muscle and urinary bladder of wild-type
and Glut2−/− animals to a similar extent, while again
very little Me-4FDG activity was detected in the brain for
either group. Consistent with our results in I.V. injected
mice (Sala-Rabanal et al. 2016), there were no significant
differences in 2-FDG uptake into liver between wild-type
and Glut2−/− mice, i.e. as percentage of absorbed tracer,
0.26± 0.05 (wild-type, n= 13) and 0.42± 0.11 (Glut2−/−,
n = 6), as measured in a 64 mm3 spherical VOI in the
right lobe (P = 0.11, Student’s t test). Similar results
have been reported for liver in another 2-FDG Glut2–/–
mouse model (Schmitt et al. 2017). In wild-type mice,
only 1% of the absorbed Me-4FDG was detected in the
Figure 3. Time course of blood glucose concentration and
activity of glucose PET tracers Me-4FDG, 2-FDG and 4-FDG
following oral delivery in mice
Following pre-treatment with SGLT1 inhibitor phlorizin (1 mg g−1) or
with phlorizin-free excipient (control), fasted wild-type mice were
administered an oral dose of glucose (2 mg g−1) with 300 μCi of
Me-4FDG (A), 2-FDG (B) or 4-FDG (C). Blood glucose concentration
(circles) and radiotracer activity (squares) were simultaneously
monitored over the next 2 h in control (filled symbols) and phlorizin
treated (open symbols) mice. The fasting blood samples (‘0 min’)
were taken immediately before phlorizin or vehicle pre-dosing. Data
are from individual experiments where phlorizin and control mice
were tested side by side, and results were confirmed in at least one
additional set of experiments with different mice for each tracer.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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urinary bladder, and also 1% of the absorbed 2-FDG,
4-FDG or Me-4FDG was found in kidney. In Glut2−/−
mice, accumulation of 2-FDG, 4FDG and Me-4FDG in
kidney, andnotably, excretion ofMe-4FDGwere increased
(Table 1).
Effect of phlorizin in Me-4FDG and 4-FDG absorption
and excretion
Figure 5 shows 1 h Me-4FDG PET images of wild-type
OGTT mice treated with excipient (control, left panel) or
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Figure 4. Absorption of orally delivered glucose PET tracers Me-4FDG, 2-FDG and 4-FDG in mice
Three hundred microcuries of Me-4FDG, 2-FDG or 4-FDG was administered by oral gavage into the stomach of
conscious control or Glut2–/– mice, and 10 min PET scans were performed after 60 min. A, volumetric renderings
of representative co-registered microPET and CT scans; PET images in this and subsequent figures are displayed
according to the NIH intensity scale for tracer activity, from red (highest), through green (intermediate) to purple
(lowest). Stomach (st), intestine (in), brain (br), urinary bladder (bl), left kidney (lk) and right kidney (rk) are
indicated where visible. B and C, gastric emptying (B) and intestinal tracer absorption (C) 60 min after oral bolus
administration in experiments as in A. Symbols represent data from individual experiments; red symbols are for
the mice shown in A. Except for Me-4FDG in Glut2–/– mice, where only two experiments were performed, bars
indicate the mean ± SEM of 6–14 experiments. No significant differences in gastric emptying (P = 0.4319) or in
tracer absorption (P = 0.766) were found between tracers or genotypes (two-way ANOVA).
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Figure 5. Me-4FDG absorption is reduced in Sglt1− /− mice, but
not in phlorizin-treated wild-type mice
Glucose (2 mg g−1) in presence of 300 μCi Me-4FDG was
administered by oral gavage into the stomach of anaesthetized
wild-type or Sglt1–/– mice, and continuous PET data were acquired
over the following 62 min; a CT scan was performed at the end of
the dynamic PET scan. Wild-type mice were pre-treated with
1 mg g−1 phlorizin, or with phlorizin-free vehicle, as described
above. Volumetric renderings of end-point co-registered images for
representative mice are shown, and their values for gastric emptying,
Me-4FDG absorption and excretion are given at the bottom. PET
images are displayed as in Fig. 4A; stomach (st), intestine (in) and
urinary bladder (bl) are indicated where visible. PET images are
displayed according to the NIH intensity scale for tracer activity, from
red (highest), through green (intermediate) to purple (lowest).
with phlorizin (middle), in comparison with an Sglt1–/–
OGTT mouse assayed under control conditions. In both
wild-typemice, about two-thirds of the oral load remained
in the stomach after 1 h, but 85–90% of the sugar
delivered into the small intestine was absorbed. The
most notable difference between these two treatments was
the significant excretion of Me-4FDG into the urinary
bladder of the phlorizin-treated animal; this suggests that
phlorizin was absorbed intact, filtered at the glomeruli,
and then inhibited Me-4FDG reabsorption by SGLTs in
the proximal tubule. In the Sglt1−/− mouse, 71% of the
initial amount of tracer in the stomach was emptied into
the intestine in1h, and49%of thatwas absorbed;however,
unlike in the case of the phlorizin-pre-treated wild-type
mouse, only 2% of the absorbed sugar was excreted into
the urinary bladder. This is consistent with the fact that
SGLT2, and not SGLT1, is largely responsible for glucose
reabsorption in the kidney.
A time course of absorption and excretion of orally
delivered 4-FDG in conscious wild-type OGTT mice
pre-dosed with vehicle (control) or with phlorizin is
shown in Fig. 6. In both groups, 65 min after bolus
administration virtually all the 4-FDG that entered the
intestine had been absorbed, but in phlorizin-treated
mice absorption was initially delayed. Thus, in control
mice, over 90% of the 4-FDG was already absorbed at
20 min, whereas in phlorizin-treated mice absorption
was 60% at 20 min and 70% at 35 min (Fig. 6B).
Conversely, 4-FDG excretion into the urinary bladder was
progressively increased in phlorizin-treated mice, up to
35% at 65 min in contrast to 7% in control mice
(Fig. 6C). Together with the results shown in Fig. 5, this
suggests thatphlorizin is absorbed intact fromthe intestine
and inhibits Me-4FDG and 4-FDG reabsorption in the
kidney.
Time dependence of glucose PET tracer intestinal
absorption
We used dynamic PET scanning to investigate the
intestinal absorption of Me-4FDG, 2-FDG and 4-FDG
in mice over time, after either orogastric gavage (Figs 7
and 8, and Videos S1 and S2) or direct delivery of the
tracers to the duodenum (Fig. 9). The time course of
Me-4FDG absorption in wild-type and Sglt1–/– mice after
oral gavage is shown in Videos S1 and S2, and Fig. 7.
Me-4FDG can only be clearly observed in the duodenum
of the wild-type mouse during the first 2 min (Video S1),
whereas the tracer can be seen throughout the intestine
of the Sglt1–/– mouse for the duration of the experiment
(Video S2). Quantitative VOI analysis revealed that once
in the intestine, absorption ofMe-4FDG inwild-typemice
was quick, and virtually completewithinminutes, whereas
in Sglt1–/– mice it was notably delayed, i.e. only 50%
of the tracer propelled from the stomach was absorbed
1 h after oral delivery (Fig. 7B). Excretion of absorbed
Me-4FDG into the urinary bladder reached a1%plateau
by 15 min in wild-type mice, but it rose linearly with time
in Sglt1–/– mice to 2% in 1 h (Fig. 7C). These results,
together with the data shown in Figs 3–6 and Table 1,
indicate that SGLT1 plays a key role in the fast absorption
of glucose across the small intestine, and that in the absence
of SGLT, intestinal glucose absorption is delayed, but not
abolished.On theotherhand, as anticipated (Sala-Rabanal
et al. 2016), the absence of SGLT1 in the kidney results only
in a slight loss of Me-4FDG and 4-FDG into the urine.
The time course of 2-FDG absorption in anaesthetized
wild-type and Glut2–/– mice after oral gavage is shown
in Fig. 8. In both groups, 2-FDG was visible in the
small intestine throughout the scan (Fig. 8A), and this
was reflected in incomplete tracer absorption, i.e. up
to 75% in wild-type and up to 60% in Glut2−/−
mice (Fig. 8B). In wild-type animals, absorbed 2-FDG
was slowly, but significantly, excreted into the urinary
bladder (Fig. 8C), consistent with inefficient reabsorption
of 2-FDG from the glomerular filtrate. 2-FDG excretion
was delayed in Glut2–/– mice (Fig. 8C), presumably due
to the lower gastric emptying, i.e. 20% in Glut2−/− vs.
40% in wild-type mice, and to the lower absorption,
i.e. 60% vs. 75%. The PET imaging studies described
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Figure 6. Phlorizin delays absorption and increases excretion of 4-FDG in mice
Following pre-treatment with phlorizin, or with phlorizin-free vehicle (control), 2 mg g−1 glucose in presence
of 300 μCi 4-FDG was administered by oral gavage into the stomach of conscious wild-type mice, and brief
10 min PET scans were performed 10, 25 or 55 min later. A, volumetric renderings of co-registered images in
three control (top) and three phlorizin-treated (bottom) mice treated side-by-side and scanned sequentially as
appropriate; results were confirmed in at least one additional trial including all time points. Stomach (st), intestine
(in) and urinary bladder (bl) are indicated where visible. B and C, 4-FDG absorption (B) and excretion (C) for the
mice shown in A. Results from each mouse are represented by a unique symbol, which is also shown to the side of
each panel in A. Data points are joined by dashed lines for illustrative purposes only. Insets, mean ± SEM of 4-FDG
absorption (B) and excretion (C) at 65 min, in three control (C) and three phlorizin-treated (P) mice. ∗P < 0.05,
Student’s t test. PET images are displayed according to the NIH intensity scale for tracer activity, from red (highest),
through green (intermediate) to purple (lowest).
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above revealed that gastric emptying is a major factor in
limiting complete glucose absorption in mouse OGTTs,
but that once delivered into the intestine, glucose is rapidly
absorbed in the duodenum. To confirm this efficient
absorption of glucose, we directly infused sugars into the
duodenum and followed the time course of absorption
by dynamic PET scanning. Figure 9 shows the results
for the administration of 200 μl of 0.9% NaCl solutions
containing (i) 5 mM α-MDG and 200 μCi Me-4FDG;
(ii) 5 mM 2-DG and 200 μCi 2-FDG; or (iii) 5 mM
glucose and 4-FDG, i.e. 1 μmol of each sugar. For each
experiment, in Fig. 9A we show coronal and sagittal PET
images of the mice 10 s, 5.5 min and 57.5 min after
delivery, and in Fig. 9B and C the time course of intestinal
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Figure 7. Dynamic Me-4FDG microPET scans of control and Sglt1− /− mice undergoing OGTTs
Glucose (2 mg g−1) in presence of 300 μCi Me-4FDG was administered by oral gavage into the stomach of
anaesthetized wild-type or Sglt1–/– mice, and continuous PET data were acquired over the following 62 min; a
CT scan was performed at the end of the dynamic PET scan. A, volumetric renderings of co-registered images
at selected times after bolus administration, for one representative wild-type mouse (top) and one representative
Sglt1–/– mouse (bottom). PET images are displayed as in Fig. 4A; stomach (st) and intestine (in) are indicated where
visible. B and C, Me-4FDG absorption (B) and excretion into urinary bladder (C) as a function of time. Data are for
the mice shown in A; gastric emptying within the first 2 min was 52% and 60%, and at the end of the experiments
was 60% and 80% in the wild-type mouse and the Sglt1–/– mouse, respectively. Similar results were obtained in
two additional experiments each. These two experiments are shown in Videos S1 and S2.
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absorption and renal excretion of each tracer. Complete
Me-4FDG and 4-FDG absorption was achieved within the
first 5 min (Fig. 9B), and there was little (< 3%) excretion
of either tracer into the urinary bladder (Fig. 9C). These
results are in agreement with our observations in OGTTs,
i.e. Me-4FDG and 4-FDG are rapidly absorbed after the
propulsion of gastric contents into the duodenum, and
2-FDG is slowly but almost completely absorbed over 1 h.
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Figure 8. Time course of 2-FDG absorption and distribution in mice
2-FDG (300 μCi) was administered by oral gavage into the stomach of anaesthetized wild-type or Glut2–/– mice,
and continuous PET data were acquired over the following 60 min; a CT scan was performed at the end of the
dynamic PET scan. A, volumetric renderings of co-registered images at selected times after bolus administration,
for one representative wild-type mouse (top) and one representative Glut2–/– mouse (bottom). PET images are
displayed as in Fig. 4A; stomach (st), intestine (in) and urinary bladder (bl) are indicated where visible. B and C,
2-FDG absorption (B) and excretion into urinary bladder (C) as a function of time. Data are the mean ± SEM for
five wild-type and three Glut2–/– mice. Gastric emptying at the end of the experiment was 40 ± 10% in wild-type
and 22 ± 10% in Glut2–/– mice (P = 0.28, Student’s t test). PET images are displayed according to the NIH intensity
scale for tracer activity, from red (highest), through green (intermediate) to purple (lowest).
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Discussion
The purpose of this study was to examine themechanisms
of glucose absorption and distribution during OGTTs
using a non-invasive imaging method, namely positron
emission tomography (PET). We are revisiting this topic
within the context of the advances in our understanding
of the molecular mechanisms of active glucose absorption
following the cloning of SGLT1 (Hediger et al. 1987;
Wright et al. 2011) and GLUT2 (James et al. 1988; Kayano
et al. 1988; Thorens et al. 1988). While the activity of
SGLT1 and GLUT2 readily explains glucose absorption at
low concentrations, it is widely recognized that glucose
‘diffusion’ becomes important at high concentrations.
It has been proposed that diffusion is due to the rapid
recruitment of intracellular GLUT2 into the brush border
membrane (Kellett, 2001). However, there is contrary
evidence to the GLUT2 hypothesis: for example (i) the
passive absorption of glucose, galactose, αMDG and
sorbose is similar in rats (Debnam & Levin, 1975), but
αMDG and sorbose are not substrates for GLUT2; (ii)
glucose OGTTs are similar in a GLUT2-null patient,
wild-type and Glut2–/– mice (Stumpel et al. 2001; Santer
et al. 2003; and see Fig. 2); and (iii) GLUT2 plays only a
minor role in glucose transport across the brush border
membrane even after a high glucose load (Gorboulev et al.
2012).
Here we re-examine the importance of SGLT1 and
GLUT2 in glucose absorption duringOGTTs usingmicro-
PET and novel glucose-specific tracers, i.e. Me-4FDG,
2-FDG and 4-FDG. The advantage of PET is that glucose
distribution throughout the entire mouse is followed
non-invasively with high spatial and temporal resolution
(Sala-Rabanal et al. 2016). Me-4FDG is a selective
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Figure 9. Dynamic Me-4FDG, 2-FDG and 4-FDG
microPET scans of control mice following direct
sugar delivery into the duodenum
Two hundred microcuries of Me-4FDG (in 5 mM α-MDG),
2-FDG (in 5 mM 2-DG) or 4-FDG (in 5 mM glucose) was
infused into the duodenum of anaesthetized mice, and
PET data were continuously acquired for 60 min. A,
coronal (c) and sagittal (s) PET images at selected times
after bolus administration for three representative mice.
Images are displayed as in Fig. 4A, and intestine (in), brain
(br), heart (h) and urinary bladder (bl) are indicated where
visible. B and C, time course of PET tracer absorption (B)
and excretion (C) for the mice shown in A. Results were
confirmed in at least one additional experiment for each
tracer.
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substrate for SGLT1 and 2-FDG is a selective substrate
for GLUTs: the apparent affinity constants of Me-4FDG
for SGLT1 and GLUT2 are 0.06 and 104 mM, respectively,
and those of 2-FDG for GLUT2 and SGLT1 are 7 and
> 300mM, respectively (Sala-Rabanal et al. 2016). Neither
Me-4FDG nor 4-FDG is metabolized in vivo, but 2-FDG
is converted intracellularly to 2-FDG-6-phosphate, which
is no longer a substrate for GLUTs. Interestingly, 2-FDG is
not significantly converted to 2-FDG-6-phosphate during
intestinal absorption, as 2-FDG accounts for > 99% of
the radioactivity detected in the blood of rats orally
dosed with 2-FDG, and the tracer is accumulated in
organs expressingGLUTs, such as brain, heart and kidneys
(Yamashita et al. 2011; and see also Figs 1 and 9). A
limitation of the studies in this work is the challenge
to carry out dynamic microPET experiments on fully
conscious rodents because of ethical concerns, but here
we circumnavigated this problem by conducting brief
scans under isoflurane anaesthesia at fixed times after oral
gavage. We find that the total amount of sugar absorbed
in conscious and anaesthetized mice is the same in these
experiments.
We chose to measure absorption under a standard
protocol for evaluating glucose homeostasis in mice and
man, namely OGTTs. In clinical studies a typical standard
testmeal consisting of 1–2 g of glucose per kg bodyweight,
i.e. 50–100 g glucose in 240–300 ml of water (1–2.5 M
glucose), is consumed after an overnight fast and blood
glucose levels are monitored for up to 2 h. In mice, we
haveperformed comparableOGTTs: 2 g kg−1 bodyweight,
i.e. 200 μl of 1.3 M glucose (equivalent to 10 pmol
of sugar per g body weight), was administered directly
into the stomach of fasting mice under light isoflurane
anaesthesia, and in the presence of 300 μCi of tracer
where appropriate. In some experiments the mouse was
allowed to recover (< 1 min) and roam freely in the cage
for up to 1 h before conducting a 10 min microPET scan,
whereas in other experiments we conducted 1 h dynamic
microPET scans.
The first major finding was that the time course of
blood Me-4FDG and 4-FDG concentration in conscious
mice closely followed that of blood glucose, both in
the presence and in the absence of phlorizin in OGTTs
(Fig. 3). However, plasma 2-FDG concentrations did not,
and the time course in the presence and absence of
phlorizin was close to those for Me-4FDG and 4-FDG
in the presence of phlorizin. Since Me-4FDG is a high
affinity substrate for SGLTs, but not GLUTs, and since
2-FDG is a specific substrate for GLUTs but not SGLTs,
these results signal the importance of SGLT1 in glucose
absorption, and suggest that GLUT2 plays a minor role
in OGTTs. This is supported by our OGTT studies in
Glut2–/– mice (Fig. 2) where changes in blood glucose
levels were indistinguishable fromOGTTs in controlmice.
In another study of the same Glut2−/− mouse model
there was a significant decrease in the blood glucose level
15 min after gavage with 4 g kg−1 body weight (Roder
et al. 2014). We also note that in another Glut2−/− mouse
model, i.e. tamoxifen-induced specific Slc2a2 deletion in
the small intestine, there was a modest reduction in blood
glucose levels in OGTTs (Schmitt et al. 2017). OGTTs
in Sglt1−/− mice have shown that blood glucose levels
remained relatively flat after gavage (Powell et al. 2012;
Gorboulev et al. 2012)
It is commonly assumed that the change in the
OGTT blood glucose profile after phlorizin pre-treatment
reflects the inhibition of glucose absorption by SGLT1.
At low concentrations, phlorizin is a specific, competitive
inhibitor of SGLT1 (Ki 140 nM; Hummel et al.
2012), but non-specific effects are reported on GLUTs
at high concentrations, > 100 μM. The initial glucose
concentration in the duodenum in OGTTs is > 1 M, but
the concentration of phlorizin is unknown. As discussed
below, phlorizin is absorbed and this results in glucose
excretion into the urinary bladder, and hence reduction of
blood glucose levels, as with oral SGLT2 inhibitors (Gallo
et al. 2015).
A second finding is that gastric emptying is a
rate-limiting step in glucose absorption in OGTTs in both
conscious and isoflurane-anaesthetized mice. On average,
only 60% of the initial stomach contents were propelled
into the small intestine ofwild-type, Sglt1−/− andGlut2−/−
mice in 1h (Fig. 4B).However, gastric emptyingwashighly
variable, ranging from 10 to 100% (Fig. 4B). These results
were comparable to previous reports using MRI imaging
(Mudie et al. 2014). The efficiency of gastric emptying
determines the delivery of glucose into the duodenum,
the time course of sugar absorption, and ultimately the
time course and peak of the post-prandial blood glucose
concentrations (Holst et al. 2016). Thus, it is highly
desirable to measure the rate of gastric emptying to inter-
pret OGTTs.
MicroPET imaging of Me-4FDG, 2-FDG and 4-FDG in
conscious mice showed that absorption of the sugar that
entered the intestine was complete within 1 h, even in
mice pre-treated with phlorizin (Figs 5 and 6). However,
at shorter times, i.e. 20 and 35 min, phlorizin partially
inhibited absorption (Fig. 6). The decreased inhibition
efficiency at later times could be due to hydrolysis of
phlorizin to inactive phloretin by the intestinal brush
border phlorizin isolactase, but this is unlikely in adult
mice as the activity of the enzyme is very low afterweaning.
Oral phlorizin pre-treatment resulted in the excretion of
sugar into the urinary bladder (Figs 5 and 6). This suggests
that phlorizin is absorbed intact from the intestine,
filtered at the glomerulus and inhibits SGLTs expressed
in the brush border membrane of the proximal tubule
(see Ghezzi et al. 2017). This implies that the reduction
in plasma glucose profiles after phlorizin pre-treatment
(Fig. 3), is, at least in part, due to excretion of glucose into
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the urine. This is the basis for the SGLT2 inhibitors used
to treat diabetes (Gallo et al. 2015; Ghezzi et al. 2017).
Dynamic microPET studies under isoflurane
anaesthesia in OGTT wild-type mice co-dosed with
Me-4FDG (e.g. Fig 7 and Video S1) show that the sugar
propelled from the stomach into the small intestine was
rapidly absorbed in the duodenum, and little Me-4FDG
was detected in the small intestine after the first few
minutes. In Sglt1−/− mice, Me-4FDG absorption was
notably delayed, i.e. 50% at 1 h compared to > 90% in
wild-typemice (Fig. 7), and this translated intoMe-4FDG
being clearly visible along the intestine throughout the
1 h study (Video S2). In similar experiments with 2-FDG
in control and Glut2–/– mice (Fig. 8), 2-FDG absorption
was slow in both groups, but 60–75% was absorbed in
1 h (Fig. 8B) and a significant fraction of the absorbed
sugar (5–15%) was excreted into the urine (Fig. 8C).
The 2-FDG filtered by the kidney glomerulus is not
reabsorbed, as 2-FDG is not a substrate for either SGLT2
or SGLT1 in the proximal tubule. The importance of
SGLT1 in glucose absorption was confirmed by the rapid
and complete absorption of 5 mM Me-4FDG and 4-FDG
delivered directly into the duodenum (Fig. 9). Absorption
of 2-FDG directly introduced into the duodenum was
slow, but practically complete after 1 h.
In OGTTs we conclude that glucose is rapidly absorbed
by SGLT1 in the early duodenum since (i) no Me-4FDG
is observed in the duodenum within minutes of gavage,
(ii) Me-4FDG is observed in the intestine at early times
after phlorizin treatment, and (iii) Me-4FDG is observed
all along the small intestine in Sglt1−/− mice. In contrast,
2-FDG is observed all along the small intestine. In the
mouse SGLT1 is expressed in the brushboardermembrane
from duodenum to ileum (Madunic et al. 2017) and this
suggests that glucose released fromcomplex carbohydrates
may be absorbed all along the small intestine.
In summary, these studies show that SGLT1 plays an
important role in the fast absorption of glucose during
OGTTs in mice, whereas GLUT2 is of minor importance.
In the absence of SGLT1, glucose is slowly absorbed in the
intestine, i.e. up to 50% in 1 h. This may account for the
small, slow increase in blood glucose in theOGTTs carried
out inmice pre-treated with phlorizin (Fig. 3).What is the
mechanism of glucose absorption in the absence of SGLT1
or GLUT2? There are at least three suggestions. (i) Passive
diffusion through enterocytes. This is reasonable as we
estimate the rate of passive absorption at 100 mM glucose
to be 500 μmol h−1, given the vast surface area of the
small intestine, i.e. 1.5 m2 (Casteleyn et al. 2010), and
a glucose permeability of 1 × 10−7 cm s−1 (Bindslev
& Wright, 1976). (ii) Diffusion through the paracellular
pathway. This is less compelling than diffusion through
the cellular pathway given the structure, permeability
properties and small relative area of the tight junctions.
Although there is strong evidence for ion permeation
through the paracellular route, there is only circumstantial
evidence for water and small-non-electrolyte permeation.
And (iii) transport through low affinity, non-selective
carriers for monosaccharides expressed in enterocytes;
however, no such transporters have been identified so
far. A similar issue occurs with glucose release from the
liver of mice where GLUT2 plays a minor role in glucose
exit (Guillam et al. 1998), and we and others did not
observe any difference between steady state 2-FDG levels
(% ID g−1) in control and Glut2−/− mice irrespective of
the route of delivery, I.V. or gavage (Sala-Rabanal et al.
2016; Schmitt et al. 2017). For both liver and intestine
Thorens has proposed that glucose exits by an exocytosis
mechanism involving glucose and de-phosphorylation
(Guillam et al. 1998; Stumpel et al. 2001), but this cannot
explain Me-4FDG or αMDG absorption as neither are
phosphorylated.
How do we interpret OGTTs in terms of sugar
absorption? This is a non-trivial task owing to the
rate-limiting effect of gastric emptying and plasma
insulin-dependent disposal of glucose into organs such
as the liver, brain and heart, and gluconeogenesis (Rizza
et al. 2016). However, using theMe-4FDGmicroPET data,
we can estimate the rate of glucose absorption. Given that
60 mg (330 μmol) is gavaged into the stomach and 60%
of this is propelled into the duodenum in 1 h (36 mg or
200 μmol), 36 mg (200 μmol) is absorbed in 1 h. SGLT1
accounts for the rapid absorption in the duodenum, and
this undoubtedly contributes to the relatively fast rise in
plasma glucose levels. In the presence of phlorizin (Fig. 3),
or the absence of SGLT1 (Powell et al. 2012; Gorboulev
et al. 2012), there is no significant increase in blood glucose
or Me-4FDG levels, but there is a slow absorption of
glucose amounting to at least 36 mg (100 μmol) over 1 h.
This slow absorption is not sufficient to cause a significant
rise in blood glucose level due to disposition of glucose
in organs throughout the body. In the case of phlorizin,
the absence of a rise in blood glucose is in part due to
the inhibition of reabsorption from the glomerular filtrate
(Fig. 6). This calls for caution in the interpretation of the
effect of other SGLT1 inhibitors on OGTTs.
Clearly, our studies do not address other factors such
as diet and fasting, or incretin secretion on OGTTs. It
is well established that during OGTTs glucose stimulates
the release of incretins though SGLT1 glucose sensing
(Gorboulev et al.2012;Roder et al.2014;Kuhre et al.2017).
However, we are not aware that these signalling molecules
influence gastric emptying or glucose absorption during
the 60 min OGTTs, but we do know that insulin does not
affect SGLT1 activity in HEK293 cells (Ghezzi & Wright,
2012).
What is the importance of GLUT2 expression on the
basolateral membranes of the intestinal epithelium, if it
does not play a major part in dietary glucose absorption?
One possibility is the supply of glucose to the enterocytes
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from the blood. Enterocytes have a high requirement for
ATP to drive salt and water absorption, and in the absence
of dietary carbohydrate, glucose from the bloodmaymeet
the demand for ATP synthesis.
Finally, there is a marked difference between the
importance of GLUT2 in intestinal and renal glucose
transport in that GLUT2 plays a minor role in
intestinal glucose absorption, whereas GLUT2 in the
kidney proximal tubule basolateral membrane is essential
for glucose reabsorption from the glomerular filtrate
(Sala-Rabanal et al. 2016). This may be due to large
differences in fluid transit times along the proximal tubule
and small intestine.
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Translational perspective
These mouse microPET studies of glucose absorption in mice clearly provide a foundation for similar
PET studies on sugar absorption in healthy human subjects and patients. Such studies may provide
insights into the importance of gastric emptying, the role of SGLT1 and GLUT2 in glucose absorption
in health and disease, and the influence of drugs, e.g. SGLT1 inhibitors being developed to treat type
2 diabetes mellitus. 2-FDG PET is already firmly entrenched in the clinic for the detection and staging
of cancer, as well as cardiac and neurological diseases, and this means that the technology is already
in place.
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Video S1: Distribution of the tracer was followed for 1 h.
Frames were collected every 2 min and the movie was
created using Amide. The maximum and minimum
thresholds of %ID g−1 used are 12 and 0, respectively.
Video S2: Distribution of the tracer was followed for
1 h. Frames were collected every 2 min and the
movie was created using Amide. The maximum and
minimum thresholds of %ID g−1 used are 12 and 0,
respectively.
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